Module 11
Computerised System Validation, Computer Software Assurance and GxP Digital System Lifecycle Control
Course Overview
This course establishes the essential foundation needed to understand, specify, validate, assure, use, maintain and inspect computerised systems in regulated pharmaceutical environments. It explains how computerised systems support product quality, patient safety, data integrity, licence compliance and regulatory confidence across the full pharmaceutical operation.
Computerised system validation and computer software assurance are not narrow IT or validation department activities. They are shared lifecycle responsibilities involving system owners, process owners, users, QA, IT, QC, production, engineering, warehouse, supply chain, regulatory affairs, procurement, suppliers, service providers and senior leadership. Any department that defines requirements, selects software, uses a GMP system, reviews electronic records, changes configuration, manages access, relies on system reports or responds to system failures can affect whether a system remains fit for intended use.
The course covers the established principles of computerised system validation, including GAMP 5, 21 CFR Part 11, EU GMP Annex 11, supplier assessment, user requirements, risk assessment, specification, testing, traceability, data migration, change control, periodic review, backup, disaster recovery, legacy systems and retirement. It also explains the modern shift towards Computer Software Assurance, showing how critical thinking and risk-based testing can reduce unnecessary documentation while strengthening confidence in systems that affect patient safety, product quality and data integrity.
Learners will understand not just what documents are expected, but how to decide what level of assurance is appropriate, how to avoid both under-validation and over-validation, and how computerised system controls are applied through the organisation’s local Pharmaceutical Quality System.
Learning Outcomes
By the end of this course, learners will be able to:
- Explain why computerised system validation and software assurance are essential to patient safety, product quality, data integrity, licence compliance and regulatory trust.
- Describe the difference between computerised system validation, computer software assurance, IT qualification, infrastructure qualification, supplier assurance and routine system governance.
- Understand the practical expectations of EU GMP Annex 11, 21 CFR Part 11 and GAMP 5 for regulated computerised systems.
- Explain why system validation must be based on intended use, process risk, data criticality, system complexity and potential impact on product quality, patient safety and data integrity.
- Recognise the responsibilities of system owners, process owners, QA, IT, users, suppliers and senior leaders in maintaining the validated or assured state.
- Develop or contribute to clear user requirements that describe what the system must do in the regulated process.
- Understand how software category, configuration, customisation, interfaces, data flows and supplier involvement influence the validation or assurance approach.
- Distinguish between scripted testing, unscripted testing, exploratory testing, automated testing, supplier testing and user acceptance testing, and understand when each may be appropriate.
- Explain how CSA supports critical thinking and risk-based assurance without weakening compliance.
- Recognise common computerised system risks, including poor requirements, excessive privileges, weak audit trail configuration, uncontrolled spreadsheets, failed interfaces, untested changes, weak supplier oversight, inadequate backup, poor data migration, unmanaged SaaS updates and undocumented workarounds.
- Identify situations that require escalation through the local PQS, including system failure, data loss, access-control concerns, audit trail anomalies, failed testing, unauthorised configuration changes, incomplete validation evidence, cybersecurity events or system use outside approved intent.
- Understand how local SOPs, system inventory, validation plans, change control, incident management, periodic review, supplier management and retirement controls operate within the organisation’s own PQS.
3.5Hrs of instructor led learning
Usable documents and templates
Real work examples and exercises
Course Content
Modern pharmaceutical organisations run on computerised systems. Laboratory results, batch records, deviations, CAPA, change controls, training records, supplier approvals, environmental monitoring, warehouse status, manufacturing instructions, maintenance records, serialisation data, regulatory documents and batch release decisions may all depend on software. If those systems are poorly specified, weakly controlled, badly validated, carelessly changed or misunderstood by users, the organisation may not be able to trust the data or decisions built on them.
EU GMP Annex 11 applies to computerised systems used as part of GMP-regulated activities and states that the application should be validated and IT infrastructure qualified. It also expects lifecycle risk management that considers patient safety, data integrity and product quality, with close cooperation between relevant personnel such as process owners, system owners, Qualified Persons and IT. That wording matters because it makes one thing painfully clear: this is not just an IT exercise.
21 CFR Part 11 sets the criteria under which FDA considers electronic records and electronic signatures to be trustworthy, reliable and generally equivalent to paper records and handwritten signatures. It applies to electronic records created, modified, maintained, archived, retrieved or transmitted under FDA records requirements, and computer systems maintained under Part 11 are subject to FDA inspection. That means electronic compliance is not decorative. It is inspection territory.
GAMP 5 Second Edition, published in July 2022, remains a key industry framework for a risk-based approach to compliant GxP computerised systems. It emphasises fit-for-intended-use systems, supplier involvement, modern software development approaches, increased critical thinking and proportionate effort.
FDA’s Computer Software Assurance guidance, finalised in September 2022, sets out a risk-based, critical-thinking approach to software assurance for production and quality system software. It is important to be precise about its regulatory scope: the CSA guidance is formally addressed under 21 CFR Part 820, the Quality System Regulation for medical devices, not under 21 CFR Parts 210 and 211, which govern pharmaceutical CGMP. The pharmaceutical industry has adopted CSA principles by analogy, supported by GAMP/ISPE endorsement of risk-based, critical-thinking approaches to testing, and the underlying philosophy is consistent with GAMP 5 Second Edition. Organisations applying CSA thinking to pharmaceutical GMP computerised systems do so on a sound technical and regulatory basis, but it remains adoption by analogy, not a direct FDA pharmaceutical CGMP requirement. The obligation to assure systems are fit for intended use, and to document sufficient evidence to support that conclusion, is fully supported by EU GMP Annex 11, GAMP 5 and good regulatory practice. CSA provides a useful and defensible framework for how that evidence is generated.
This course is essential because computerised system control is a shared business responsibility. Process owners must understand what the system does in their regulated work. System owners must govern the system through its lifecycle. QA must verify that controls are adequate. IT must manage infrastructure, security and operational support. Users must know how to operate the system correctly and recognise when something is wrong. Suppliers must deliver and maintain what they have promised. Senior leadership must invest, prioritise and accept residual risk consciously.
A beautifully validated system used badly is still a compliance problem, and a beautifully assured system without proper governance is no improvement.
Defining the Regulated Computerised System
The course begins by establishing what counts as a computerised system in a GMP context, what GxP impact means, and how to determine whether a system requires validation, assurance, IT qualification or routine governance. Learners will understand how to build and maintain a defensible system inventory and how to triage new systems entering the regulated environment.
The Regulatory Framework: Annex 11, 21 Cfr Part 11 and GAMP 5
The regulatory framework is then introduced in practical terms. EU GMP Annex 11, 21 CFR Part 11 and GAMP 5 Second Edition are explained as complementary, not competing, frameworks. The course covers what each expects, where they overlap, where they diverge and how organisations operating across both EU and US markets should align their approach.
GAMP 5 Risk-Based Approach
A dedicated section covers the GAMP 5 risk-based approach. Learners will understand software categorisation (Categories 1, 3, 4 and 5), the implications of each category for validation depth, how to assess intended use, how to perform initial risk assessment, how to scale specification and testing to risk, and how supplier involvement and supplier assurance reduce or shift validation effort.
Computer Software Assurance and Risk-Based Testing
Computer Software Assurance is then explained as a development of risk-based thinking rather than a replacement for it. Learners will understand the difference between unscripted, exploratory, scripted and automated testing, when each is appropriate, and how to document evidence that is sufficient to support assurance without generating documentation that obscures rather than supports understanding. The course is explicit about CSA’s regulatory scope (formally addressed to medical device quality system software under 21 CFR Part 820) and explains how and why the pharmaceutical industry applies CSA principles by analogy under GMP frameworks. CSA is critical thinking, risk-based assurance and appropriate evidence. It is not validation on a diet, and the organisation, not the framework, owns the risk.
Data Flows and Interfaces
The course also covers data flows and interfaces. Learners will understand how data move between systems such as LIMS, ERP, MES, QMS, LMS, WMS, CDS, environmental monitoring systems, maintenance systems and regulatory document platforms. The course explains the risks created by data transfer, manual transcription, report generation, spreadsheet exports, middleware, interface failures, duplicate records and mismatched master data.
Legacy Systems
Legacy systems are covered in a practical and realistic way. Learners will understand how to assess older systems that remain in GMP use, including validation gaps, unsupported software, obsolete operating systems, missing supplier support, limited audit trail functionality, restricted backup options and cybersecurity vulnerabilities. The course explains how to build a defensible remediation, replacement or risk-acceptance strategy rather than pretending the system is fine because “it has always worked.”
Computerised System Controls Across Departments
The course then examines how computerised system controls apply across different departments:
- QC laboratories: chromatography systems, LIMS, instrument software, electronic worksheets, audit trails and raw data management.
- Production and packaging: MES, electronic batch records, automation systems, recipe management, line systems and serialisation interfaces.
- QA: eQMS platforms for deviations, CAPA, change control, complaints, audit management and document control.
- Engineering and maintenance: calibration systems, maintenance systems, building management systems, utility monitoring and automation platforms.
- Warehouse and supply chain: ERP, WMS, temperature-monitoring systems, stock status, supplier data and distribution interfaces.
- Training and HR: learning management systems, training records, role-based curricula and competency evidence.
- Regulatory affairs: regulatory document systems, submission platforms, registered information and controlled product data.
- Procurement and supplier quality: supplier portals, vendor qualification platforms, service-provider records and supplier change notifications.
- Senior leadership: governance, resource decisions, prioritisation of remediation, risk acceptance and digital transformation oversight.
Maintaining the Validated or Assured State
The course includes a strong focus on maintaining the validated or assured state. Learners will understand how change control, release management, configuration management, access review, periodic review, incident management, deviation escalation, CAPA, supplier monitoring, audit trail review and business continuity planning all contribute to ongoing compliance.
Cybersecurity and Operational Resilience
Cybersecurity and operational resilience are also addressed at the right level for GMP system governance. Learners will understand how cybersecurity events, ransomware, unauthorised access, system unavailability, poor patching, unsupported systems and weak disaster recovery can become quality and data integrity risks. This section avoids turning the course into an IT security qualification, but it makes clear that cyber resilience is now part of protecting regulated operations.
Inspection Readiness for Computerised Systems
The final section focuses on inspection readiness. Learners will understand what inspectors typically look for: a complete system inventory, clear GxP impact assessment, justified validation approach, approved requirements, traceable testing, controlled deviations, supplier assessment, access control, audit trail configuration, backup and recovery evidence, periodic review, change history, incident records and evidence that users understand the system. Inspectors are not reassured by a giant validation pack if nobody can explain what the system does, what risks it controls or why the evidence is sufficient.
- Employees, contractors and third parties involved in selecting, specifying, configuring, validating, testing, approving, using, maintaining, changing, reviewing or retiring GMP-impacting computerised
- IT validation engineers, CSV specialists, CSA leads and validation
- System owners and business process owners responsible for GxP
- QA professionals responsible for computerised system oversight, eQMS platforms, validation approval, data integrity, audit readiness or inspection support.
- IT, digital, automation, infrastructure and cybersecurity professionals supporting regulated pharmaceutical systems.
- QC analysts, laboratory managers and technical specialists using LIMS, chromatography systems, laboratory instruments or electronic worksheets.
- Production, packaging and operations personnel using MES, electronic batch records, automation systems, recipe controls, packaging systems or serialisation platforms.
- Engineering, facilities and maintenance teams using calibration systems, BMS, EMS, maintenance platforms, utilities monitoring or automated control systems.
- Warehouse, logistics and supply chain teams using ERP, WMS, temperature-monitoring systems and supplier or inventory platforms.
- Regulatory affairs, pharmacovigilance and medical information interface teams using controlled electronic records or submission platforms.
- Procurement and supplier quality teams involved in software supplier selection, SaaS contracts, outsourced platforms or vendor documentation.
- QPs, site quality heads, operations leaders and senior managers accountable for digital system governance, resources, risk acceptance and inspection readiness.
You will gain a practical understanding of how computerised systems are validated, assured and maintained in pharmaceutical environments. You will be able to understand the language of CSV and CSA, contribute to user requirements, recognise system risks, challenge weak validation approaches and identify when a system issue needs escalation.
For IT, QA, validation and system-owner roles, this course gives you the foundation needed to design and defend risk-based validation and assurance strategies. For operational users and department managers, it explains why your input matters: a system cannot be properly assured if the people who understand the process are not involved.
You will also be better equipped to work with suppliers, auditors and inspectors because you will understand the difference between useful validation evidence and paperwork generated by nervousness. That distinction alone is worth its weight in toner.
Organisations benefit from a workforce that understands computerised system control as a shared lifecycle responsibility rather than an IT validation paperwork exercise. This reduces the risk of poorly specified systems, inadequate testing, weak access control, unmanaged changes, unreliable electronic records, failed interfaces, uncontrolled spreadsheets, legacy-system exposure and inspection findings.
The course supports better collaboration between QA, IT, system owners, process owners, operational users, suppliers and senior leaders. That collaboration is essential because computerised system failures usually occur at the interfaces: between user need and system configuration, between supplier promise and regulated use, between IT change and GMP impact, between electronic data and quality decision, or between digital ambition and actual control.
A good CSV or CSA programme does not merely produce validation documents. It ensures that systems are fit for intended use, data are trustworthy, users are competent, changes are controlled and risks are understood. That is what regulators expect, and it is also what sensible companies need before placing major quality decisions in the hands of software.
- Comprehensive expert video
- Real-world case studies from pharmaceutical manufacturing, laboratory, packaging, warehouse, quality systems, IT, automation, cloud/SaaS and regulatory environments.
- Practical examples covering GAMP 5, 21 CFR Part 11, EU GMP Annex 11, CSV lifecycle, CSA principles, system categorisation and risk-based assurance.
- Cross-functional scenarios showing how system owners, process owners, QA, IT, users, suppliers and leaders affect computerised system compliance.
- Exercises on GxP impact assessment, user requirements, software categorisation, risk assessment, test strategy, traceability, supplier documentation and escalation through the local PQS.
- Practical examples of scripted testing, unscripted testing, exploratory testing, supplier testing, automated testing and exception-based reporting.
- Scenarios covering data migration, interfaces, access control, audit trails, SaaS updates, legacy systems, backup, disaster recovery, cybersecurity events and system retirement.
- Inspection-readiness scenarios focused on defending validation strategy, system risk rationale, requirements, testing evidence, deviations, change controls and periodic review.
- Multi-choice assessment
- Certificate of completion upon passing the
Course Details
Instructor(s):
Paul Palmer & Farah Nadeem
Level:
Practitioner
Duration:
3.5 Hours
Type:
Instructor led
Launch Yourself Into The Future.
Join Academy Pharmaceutical Excellence to gain industry-leading knowledge and skills through our comprehensive courses designed for aspiring professionals.